Top

Journal of Neurology

Published in:

01-05-2017 | Letter to the Editors

Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases

Authors: Daniele Velardo, Nilo Riva, Ubaldo Del Carro, Francesca Bianchi, Giancarlo Comi, Raffaella Fazio

Published in: Journal of Neurology | Issue 5/2017

Excerpt

Dear Sirs, …

Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK (1999) Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 66:677–680CrossRefPubMedPubMedCentral

Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, Taylor BV, Dyck PJ, Kiernan MC, Lin CS (2015) Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 86(9):973–985CrossRefPubMedPubMedCentral

Koller H, Kieseier B, Jander S, Hartung H (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356CrossRefPubMed

Mahdi-Rogers M, van Doorn PA, Hughes RA (2013) Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (6):CD003280

European Federation of Neurological Societies/Peripheral Nerve Society (2010) Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society–First Revision. Joint Task Force of the EFNS and the PNS. J Peripher Nerv Syst 15(1):1–9

Martinenghi S, Comi G, Galardi G, Di Carlo V, Pozza G, Secchi A (1997) Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycaemic control provided by the pancreas. Diabetologia 40(9):1110–1112CrossRefPubMed

Stathopoulos P, Alexopoulos H, Dalakas MC (2015) Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol. 11(3):143–156CrossRefPubMed

Briani C, Zara G, Zambello R et al (2004) Rituximab-responsive CIDP. Eur J Neurol 11(788e):91

Knecht H, Baumberger M, Tobon A, Steck A (2004) Sustained remission of CIDP associated with Evans syndrome. Neurology 63(4):730–732CrossRefPubMed

10.

Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D (2011) Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82(3):306–308CrossRefPubMed

11.

D’Amico A, Catteruccia M, De Benedetti F, Vivarelli M, Colucci M, Cascioli S, Bertini E (2012) Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol. 16(3):301–303CrossRefPubMed

12.

Sanz PG, García Méndez CV, Cueto AL, Silva VB, Walther JC, Diez RA, Martins S, Giannaula RJ (2012) Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment. Rheumatol Int 32(12):4061–4063CrossRefPubMed

13.

Ware TL, Kornberg AJ, Rodriguez-Casero MV, Ryan MM (2014) Childhood chronic inflammatory demyelinating polyneuropathy: an overview of 10 cases in the modern era. J Child Neurol 29(1):43–48CrossRefPubMed

14.

Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Seró-Ballesteros L, Carvajal A, Ortiz N, Gallardo E, Illa I (2015) Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2(5):e149CrossRefPubMedPubMedCentral

15.

Gorson KC, Natarajan N, Ropper AH, Weinstein R (2007) Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35(1):66–69CrossRefPubMed

16.

Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, Briani C, Fazio R, Jann S, Matà S, Sabatelli M (2011) Nobile-Orazio E; Italian Network for CIDP Register. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 18(12):1417–1421CrossRefPubMed

Title: Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases
Authors: Daniele Velardo
Nilo Riva
Ubaldo Del Carro
Francesca Bianchi
Giancarlo Comi
Raffaella Fazio
Publication date: 01-05-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 5/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8462-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2017

Medial temporal lobe epilepsy associated with hippocampal sclerosis is a distinctive syndrome

Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women

Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy

Capturing saccades in multiple sclerosis with a digitized test of rapid number naming

Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS

Long-term outcomes of refractory neurosarcoidosis treated with infliximab